ArticleEuropean journal of medical research2025
HDAC2 mediates the activation of macrophage in sepsis induced lung injury via regulating the acetylation of SOX2 and the transcription of STAMP2.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundSepsis, characterized by a severe systemic inflammatory response leading to organ failure, often results in acute respiratory dysfunction in approximately half of affected individuals. Understanding the molecular mechanisms underlying pulmonary impairment in sepsis is critical for advancing clinical interventions. This study aimed to investigate the role and mechanism of histone deacetylase 2 (HDAC2) in the progression of septic lung injury (SLI).
methodsTo establish the SLI model, cecal ligation and puncture (CLP) was performed in vivo. Hematoxylin-eosin (HE) staining was used to assess pathological changes in lung tissue. For in vitro experiments, lipopolysaccharide (LPS)-induced macrophages were employed to model SLI. Macrophage activation was evaluated by analyzing the expression levels of F4/80, inducible nitric oxide synthase (iNOS), and CD86. Protein-protein interactions were analyzed via co-immunoprecipitation (CO-IP), while transcriptional regulation was examined using luciferase assays and chromatin immunoprecipitation (ChIP).
resultsThe findings demonstrated that HDAC2 knockdown mitigates SLI severity and suppresses macrophage activation. Mechanistically, HDAC2 directly interacts with SOX2 to inhibit its acetylation and destabilize the protein. Furthermore, SOX2 binds to the STAMP2 promoter region and modulates its transcriptional activity.
conclusionCollectively, the HDAC2/SOX2/STAMP2 signaling axis represents a potential therapeutic target for the treatment of septic lung injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.